Puma Biotechnology Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Puma Biotech's Nerlynx remains a dud. Will a breast cancer expansion turn things around? | Fierce Pharma
Puma Biotechnology to Participate in Panel Discussion at Citi's Biotech Conference
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech Receives Positive CHMP Opinion, Spikes Share Price | INN
Puma Biotech to pay PPD founder $22M in defamation suit from proxy fight | Fierce Pharma
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
3 Takeaways from Puma Biotechnology's 2018 Earnings | The Motley Fool
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology
CSM Press Release - Puma
Puma Biotech Expands Pierre Fabre License to Add Countries
Quartal Beschreibend Perlen puma biotech press release Region Kapitalismus Essen
Puma Biotechnology
Quartal Beschreibend Perlen puma biotech press release Region Kapitalismus Essen
Puma Biotechnology
PRESS RELEASE PUMA appoints Björn Gulden as ... - About PUMA
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
